Main Menu

Licensing and partnering opportunities

The Institute of Cancer Research currently has a number of partnering and licensing opportunities and any member of the Enterprise Unit would be pleased to review these with potential commercial collaborators. 

Abiraterone, a drug used to treat advanced prostate cancer was discovered and developed at the ICR
A summary of our current partnership opportunities is provided below. You can find out more about these by downloading our latest licensing and partnering portfolio (PDF, 20.9KB). Please contact the Enterprise Unit if you'd like to discuss these opportunities further.
 
  • Biomarkers: An approach to targeting SMARCB1-deficient sarcomas
  • Biomarkers: Diagnostic for sensitivity to ATR inhibition
  • Biomarkers: Biomarker to identify patients for CDK4/6 inhibitor treatment
  • Biomarkers: Biomarker to identify patients for PARP inhibitor treatment
  • Devices: Device for tissue processing
  • Devices: Endocovitary coil for 3T-MRI
  • Devices: PolyScope
  • Targeting: Monocolonal antibodies against Cerb-B2 (HER2)
  • Targeting: Monocolonal antibodies against EGFR
  • Therapeutics: Gene Directed Enzyme Prodrug Therapy
  • Therapeutics: Novel dual inhibitors of FLT3/Aurora kinases
  • Therapeutics: Novel LOX inhibitors

Download licensing and partnering portfolio